Leerink steps to sidelines on Amicus amid lack of near-term catalysts

|About: Amicus Therapeutics, Inc. (FOLD)|By:, SA News Editor

Leerink cuts Amicus Therapeutics (FOLD -2.5%) to Market Perform from Outperform.

Analyst Joseph Schwartz sees "relatively limited news flow over the near-term" and thinks the company's "aim of offering an enzyme replacement therapy that is optimized with a coformulated pharmacologic chaperone for every lysosomal storage disorder [is] compelling but may take some time."

Price target is $3.